FDA Inspection
Reliance Life Sciences Private LimitedReliance Life Sciences Private Limited – FDA Inspection, Feb 22, 2019
Record Details
This FDA Inspection record concerns Reliance Life Sciences Private Limited, with an inspection on February 22, 2019, issued by the Office of Inspections and Investigations, covering human drugs.
- Inspection Date
- February 22, 2019
- Product Type
- Human Drugs
View Company Profile
ID · f95a3d58-e9f3-4080-8e57-56a6cf432d59
Inspection Facts
Voluntary Action Indicated (VAI)
Objectionable conditions were found, but FDA is not prepared to take or recommend regulatory action.
- Inspection number
- 1081821
- FDA center
- Human Drugs
- Project area
- Generic Drug Evaluation
- Outcome
- Form 483 issued
FDA Citations
1- 21 CFR 310.305(a)Failure to develop written procedures
Full citation text and observation details available on the Dashboard.
Other FDA inspections of Reliance Life Sciences Private Limited
9| Date | Classification | Office | Project area |
|---|---|---|---|
| February 27, 2026 | Not classified | Office of Inspections and Investigations | |
| April 15, 2022 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
| November 22, 2019 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| October 16, 2018 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| January 25, 2018 | NAI | Center for Drug Evaluation and Research | Bioresearch Monitoring |
Other documents for Reliance Life Sciences Private Limited
- FDA Inspection 1311632 - 2026-02-27
- FDA Inspection 1170339 - 2022-04-15
- FDA Inspection 1113122 - 2019-11-22
- FDA Inspection 1070144 - 2018-10-16
- FDA Inspection 1047623 - 2018-01-25
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.